Polyrizon Ltd. (NASDAQ: PLRZ) filed a divisional patent application with the European Patent Office on April 27, 2026 for its Trap & Target (T&T) intranasal drug‑delivery platform, expanding the company’s intellectual‑property portfolio in a rapidly growing market.
Continue reading for full analysis...
Polyrizon Ltd. (NASDAQ: PLRZ) completed a direct offering and a concurrent private placement of 388,888 units on April 7 2026, raising approximately $3.5 million in new capital. Each unit consists of one ordinary share (or one pre‑funded warrant to purchase one ordinary share) and one common warrant to purchase one ordinary share, giving investors both equity and warrant exposure.
Continue reading for full analysis...